Advertisement
Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Editor-in-Chief: Alex A. Adjei, MD, PhD, FACP
ISSN: 1556-0864
Online ISSN: 1556-1380
Frequency: 12 issues / year
Ranking: Oncology 54/194
Respiratory System 9/48
Impact Factor: 3.661

Current Issue: June 2013 - Volume 8 - Issue 6

Current Issue Highlights

Actions
View
Actions
View
Login

Quick Poll

For coverage of this subject, please see Hirsch FR et al, J Thorac Oncol, 8: 373 -384, 2013

A 57-year old “never-smoker” is referred to you for a second opinion. She was diagnosed with metastatic NSCLC 12 months ago. She was started on paclitaxel/carboplatin, bevacizumab for 6 cycles with a partial response. Maintenance bevacizumab has been discontinued because of progressive disease. You order EGFR mutational testing which demonstrated an exon 19 deletion. She goes back to her local oncologist on erlotinib. She is sent to you 3 months later for recommendations for therapy of acquired resistance to erlotinib. The criteria for defining acquired resistance to EGFR TKIs include:
A 57-year old “never-smoker” is referred to you for a second opinion. She was diagnosed with metastatic NSCLC 12 months ago. She was started on paclitaxel/carboplatin, bevacizumab for 6 cycles with a partial response. Maintenance bevacizumab has been discontinued because of progressive disease. You order EGFR mutational testing which demonstrated an exon 19 deletion. She goes back to her local oncologist on erlotinib. She is sent to you 3 months later for recommendations for therapy of acquired resistance to erlotinib. The criteria for defining acquired resistance to EGFR TKIs include:
A 57-year old “never-smoker” is referred to you for a second opinion. She was diagnosed with metastatic NSCLC 12 months ago. She was started on paclitaxel/carboplatin, bevacizumab for 6 cycles with a partial response. Maintenance bevacizumab has been discontinued because of progressive disease. You order EGFR mutational testing which demonstrated an exon 19 deletion. She goes back to her local oncologist on erlotinib. She is sent to you 3 months later for recommendations for therapy of acquired resistance to erlotinib. The criteria for defining acquired resistance to EGFR TKIs include:
A 57-year old “never-smoker” is referred to you for a second opinion. She was diagnosed with metastatic NSCLC 12 months ago. She was started on paclitaxel/carboplatin, bevacizumab for 6 cycles with a partial response. Maintenance bevacizumab has been discontinued because of progressive disease. You order EGFR mutational testing which demonstrated an exon 19 deletion. She goes back to her local oncologist on erlotinib. She is sent to you 3 months later for recommendations for therapy of acquired resistance to erlotinib. The criteria for defining acquired resistance to EGFR TKIs include:
A 57-year old “never-smoker” is referred to you for a second opinion. She was diagnosed with metastatic NSCLC 12 months ago. She was started on paclitaxel/carboplatin, bevacizumab for 6 cycles with a partial response. Maintenance bevacizumab has been discontinued because of progressive disease. You order EGFR mutational testing which demonstrated an exon 19 deletion. She goes back to her local oncologist on erlotinib. She is sent to you 3 months later for recommendations for therapy of acquired resistance to erlotinib. The criteria for defining acquired resistance to EGFR TKIs include:
A 57-year old “never-smoker” is referred to you for a second opinion. She was diagnosed with metastatic NSCLC 12 months ago. She was started on paclitaxel/carboplatin, bevacizumab for 6 cycles with a partial response. Maintenance bevacizumab has been discontinued because of progressive disease. You order EGFR mutational testing which demonstrated an exon 19 deletion. She goes back to her local oncologist on erlotinib. She is sent to you 3 months later for recommendations for therapy of acquired resistance to erlotinib. The criteria for defining acquired resistance to EGFR TKIs include:
A 57-year old “never-smoker” is referred to you for a second opinion. She was diagnosed with metastatic NSCLC 12 months ago. She was started on paclitaxel/carboplatin, bevacizumab for 6 cycles with a partial response. Maintenance bevacizumab has been discontinued because of progressive disease. You order EGFR mutational testing which demonstrated an exon 19 deletion. She goes back to her local oncologist on erlotinib. She is sent to you 3 months later for recommendations for therapy of acquired resistance to erlotinib. The criteria for defining acquired resistance to EGFR TKIs include:
 Submit
 Clear
 Results
Foreign Language Editions

JTO is proud to present translations of its content into French and Chinese. We sincerely thank  Jean-Louis Pujol, Wu Yilong, and Tony Mok for their work on the French and Chinese editions.  

French, Selected Articles

French JTO, Vol 1 Issue 1

French JTO, Vol 1 Issue 2

French JTO, Vol 1 Issue 3

 

Chinese, Selected Articles

Chinese JTO, Vol 2 Issue 2

 
Call for Videos
JTO accepts videos as supplemental content to articles. Submission guidelines online.
Advertisement
Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.
Advertisement